CANSINOBIO (06185) announced that the Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), PCV24, has officially commenced, with the first participant enrolled. The company's PCV24 received clinical trial approval from China's National Medical Products Administration (NMPA) in January 2026. This vaccine covers the major prevalent pneumococcal serotypes and utilizes a covalent conjugation method of polysaccharide antigens to protein carriers, along with a dual-carrier technology. It is intended for immunization of individuals aged 2 months (minimum 6 weeks) and older to prevent infections caused by 24 pneumococcal serotypes. The company's 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), marketed under the brand name Youpeixin®, received NMPA approval for its New Drug Application in June 2025. PCV24 represents a further expansion of the company's pneumococcal product portfolio. As of the date of this announcement, there are no commercially available 24-valent pneumococcal conjugate vaccines in any market globally. The Phase I/II clinical trial is designed to evaluate the safety and immunogenicity of PCV24 in individuals aged 2 months (minimum 6 weeks) and older.